iVascular released the first data release from the OPAL study, presenting results of the OPAL premarket study evaluating Amber Liquid Embolic at CIRSE 2026.
Published
Signal category
Research & Knowledge
Quote
“First data release from the OPAL study. Dr. Fernando Gómez presented, for the first time, the results of the OPAL premarket study evaluating Amber Liquid Embolic at #CIRSE2026.”
— iVascular team
Company
iVascular
Therapies for living.
- Industry
- Medical Equipment Manufacturing
- Location
- Freiburg im Breisgau, DE
- Company size
- 301 employees
The purpose of iVascular is to provide advanced medical devices and therapies for the treatment of disorders of the cardiovascular system. Thanks to the know-how provided by our technicians and an appropriate investment in technology, iVascular has implemented a vertical integration project allowing it to produce vascular devices from basic raw materials (plastics, polymers, metals...) to the final device. iVascular possesses and develops its own technologies, which have made possible the vertical integration of each and every one of the processes involved in developing a device. In this way, we guarantee the highest quality standards in all our products. Through its direct and indirect sales network, iVascular is present in more than 80 countries around the world and provides a full range of products for interventional cardiology, endovascular procedures, and neurointervention. For more information about iVascular, please visit www.ivascular.global. If you have any questions or comments, we are ready to help you out by email at info@ivascular.global
Founded 2010